Literature DB >> 9616172

Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.

D G Spiller1, R V Giles, J Grzybowski, D M Tidd, R E Clark.   

Abstract

The hybrid gene BCR-ABL that typifies chronic myeloid leukemia (CML) represents an attractive target for therapy with antisense oligodeoxyribonucleotides (ODN). A central obstacle in the therapeutic application of ODN is their poor cellular uptake. Adding various lipophilic conjugates to the ODN backbone has been reported to improve uptake, and electroporation of target cells has also been shown to enhance intracellular ODN delivery. We have shown that (1) BCR-ABL-directed ODN will specifically decrease the level of BCR-ABL mRNA, provided that cells are first permeabilized with Streptolysin-O (SL-O), and (2) chimeric methylphosphonodiester:phosphodiester ODN directed against 9 bases either side of the BCR-ABL junction are more efficient ODN effectors than structures composed solely of phosphodiester or phosphorothioate linkages. In this study, we compared the efficacy of lipophilic conjugation, SL-O permeabilization and electroporation on the intracellular delivery and molecular effect of BCR-ABL-directed ODN. b2a2- and b3a2-directed chimeric ODN were synthesized either unmodified or with one of the following groups at the 5' end: cholesterol, vitamin E, polyethylene glycol of average molecular weight 2,000 or 5,000, N-octyl-oligo-oxyethylene, or dodecanol. ODN associated with Lipofectin was also studied. Comparison was made in untreated, electroporated, and SL-O permeabilized KYO1 cells. Uptake was examined by fluorescence microscopy and flow cytometry, using ODN structures that were 3' labeled with fluorescein. The effect on target BCR-ABL mRNA expression was analyzed by Northern blotting. Several conjugated structures associated avidly with the cell membrane without achieving significant intracellular uptake or molecular effect. Similarly, ODN:Lipofectin complexes moderately increased cell association, without enhancing intracellular levels of ODN or inducing detectable molecular effect. In SL-O permeabilized or electroporated cells, uptake was approximately 1 to 2 logs greater than in untreated cells, and rapid nuclear localization was seen, especially with unmodified chimeric ODN. In SL-O permeabilized cells treated with ODN directed to the b2a2 and b3a2 junctions respectively, b2a2 BCR-ABL mRNA levels at 4 hours were reduced to 2. 6% +/- 2.1% and 38.4% +/- 1.3% of control values. In cells permeabilized by electroporation, BCR-ABL mRNA levels were decreased to 4.0% +/- 1.4% of control levels by b2a2 directed ODN, although very little nontargeted suppression was seen with b3a2-targeted ODN (93.4% +/- 4.2% of control). Greater cell to cell variation in ODN uptake was seen for SL-O permeabilized cells when compared with electroporated cells, suggesting that, after SL-O permeabilization, relatively unpermeabilized and overpermeabilized populations may coexist. No structure had any effect on the level of irrelevant (p53, MYC, and GADPH) mRNA levels. We conclude that the conjugation of chimeric ODN with one of the above-mentioned lipophilic groups or the complexing of ODN with Liopfectin does not improve either intracellular delivery of ODN or the molecular effect. In contrast, both electroporation and SL-O permeabilization (1) considerably enhanced uptake of chimeric ODN (even for structures without a conjugate group) and (2) achieved significant suppression of target mRNA levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616172

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The many ways to cross the plasma membrane.

Authors:  D J Stephens; R Pepperkok
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  Cytoplasmic molecular delivery with shock waves: importance of impulse.

Authors:  T Kodama; M R Hamblin; A G Doukas
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

4.  Dynamics of native β-actin mRNA transport in the cytoplasm.

Authors:  Aaron W Lifland; Chiara Zurla; Joana Yu; Philip J Santangelo
Journal:  Traffic       Date:  2011-05-18       Impact factor: 6.215

Review 5.  Imaging viral RNA using multiply labeled tetravalent RNA imaging probes in live cells.

Authors:  Eric Alonas; Daryll Vanover; Emmeline Blanchard; Chiara Zurla; Philip J Santangelo
Journal:  Methods       Date:  2016-02-12       Impact factor: 3.608

6.  Probes for intracellular RNA imaging in live cells.

Authors:  Philip J Santangelo; Eric Alonas; Jeenah Jung; Aaron W Lifland; Chiara Zurla
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 7.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

8.  Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

Authors:  Rathi N Pillai; Lisa S Chen; Mary L Ayres; Billie J Nowak; Michael W Thomas; Elizabeth J Shpall; Michael J Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2012-04-23

9.  Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway.

Authors:  Mi-Jung Lee; Jee-Youn Kim; Kyoungho Suk; Jae-Hoon Park
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

10.  In vivo colocalisation of oskar mRNA and trans-acting proteins revealed by quantitative imaging of the Drosophila oocyte.

Authors:  Musa M Mhlanga; Diana P Bratu; Auguste Genovesio; Agata Rybarska; Nicolas Chenouard; Ulf Nehrbass; Jean-Christophe Olivo-Marin
Journal:  PLoS One       Date:  2009-07-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.